Whole Genome Sequencing for Nephrotic Syndrome Discovery
用于发现肾病综合征的全基因组测序
基本信息
- 批准号:10115553
- 负责人:
- 金额:$ 56.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-18 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Abstract
Primary nephrotic syndrome (NS) is a rare disease of glomerular filtration barrier failure that causes
massive urinary excretion of protein. Morbidity and mortality from NS is related both to the disease and the non-
specific medications used to try to treat it. NS is currently classified and treated according to histologic
appearance (e.g. focal segmental glomerulosclerosis [FSGS], minimal change disease[MCD]) or response to
steroid therapy. This descriptive taxonomy is nonspecific and does not illuminate NS's underlying pathobiology.
To achieve increasingly precise and effective care for NS patients, a better understanding of its underlying
molecular mechanisms is necessary. Human genetics studies in NS have proven a promising strategy to permit
patient classification by molecular subtype and identify targets that will spur biomarker and drug discovery.
To discover novel, and identify known, genetic determinants of NS, their clinical correlates, and the
mechanisms by which they confer their harm, we are generating and analyzing deep whole genome sequencing
and RNA-seq derived transcriptomic data from affected patients in a North American, population-based cohort.
Using gene expression from the kidneys of patients with NS, we aim to discover genetic variants associated with
NS via expression quantitative trait loci (eQTL) studies. Using eQTLs as an intermediate molecular phenotype
improves power to detect significant associations and will also directly illuminate biologic pathways that would
not have been detected otherwise. We will also determine the prevalence of known monogenic forms NS in this
cohort using robust bioinformatics filtering paired with functional testing. We will describe clinical correlates via
integration with baseline and longitudinal phenotyping. Beyond the polygenic model, we are equally determined
to discover the penetrance of the immunosuppressant resistant phenotype among patients with Mendelian NS.
Our lab has thus far performed preliminary eQTL and Mendelian studies on enrollees in the Nephrotic
Syndrome Study Network, with promising results. Here, we will expand these studies, beginning in Aim 1 by
using new WGS and RNA-seq datasets to discover glomerular and tubulointerstitial eQTLs and identify those
specific to these kidney tissues vs other tissues. In Aim 2, we will localize these eQTLs to specific cell lineages
via integration with single cell RNA-Seq data, identify those overlapping kidney-derived regulatory regions, and
discover their association with biologic processes and clinical phenotypes. We will functionally test top candidate
eQTLs in drosophila and kidney organoid systems. In Aim 3, we will use WGS data to discover the prevalence
of NS due to known Mendelian causes. We will study clinical correlates of Mendelian NS in US patients and
identify factors associated with complete remission among those with Mendelian disease. Finally, we will use the
drosophila and organoids models to functionally screen the putative pathogenic variants we discover. Altogether,
we expect these discoveries to expand our knowledge of the spectrum of NS-associated genetic variation, the
clinical implications for those harboring them, and the mechanisms underlying their pathogenicity.
摘要
原发性肾病综合征(NS)是一种罕见的肾小球滤过屏障功能衰竭的疾病,
大量的蛋白质从尿中排出。NS的发病率和死亡率与疾病和非疾病相关。
NS目前根据组织学分类和治疗,
外观(如局灶节段性肾小球硬化[FSGS]、微小病变疾病[MCD])或对
类固醇治疗这种描述性分类是非特异性的,并没有阐明NS的潜在病理生物学。
为了实现对NS患者越来越精确和有效的护理,更好地了解其潜在的
分子机制是必要的。NS中的人类遗传学研究已证明是一种有前途的策略,
通过分子亚型对患者进行分类,并确定将刺激生物标志物和药物发现的靶点。
发现新的,并确定已知的,遗传决定因素的NS,其临床相关性,和
我们正在生成和分析深层的全基因组测序,
和RNA-seq从北美基于人群的队列中的受影响患者获得转录组数据。
利用NS患者肾脏的基因表达,我们的目标是发现与NS相关的遗传变异。
NS通过表达数量性状基因座(eQTL)研究。利用eQTL作为中间分子表型
提高了检测重要关联的能力,也将直接阐明生物学途径,
没有被发现,否则。我们还将确定已知的单基因型NS在本研究中的流行率。
使用强大的生物信息学过滤与功能测试配对的队列。我们将通过以下方式描述临床相关性:
与基线和纵向表型的整合。在多基因模型之外,我们同样决心
目的:探讨孟德尔遗传性肾病综合征患者免疫抑制剂耐药表型的发生率。
到目前为止,我们的实验室已经对肾病患者进行了初步的eQTL和孟德尔研究。
综合征研究网络,取得了可喜的成果。在这里,我们将扩展这些研究,从目标1开始,
使用新的WGS和RNA-seq数据集来发现肾小球和肾小管间质eQTL,并鉴定这些eQTL。
对这些肾脏组织和其他组织的特异性。在目标2中,我们将这些eQTL定位到特定的细胞谱系,
通过整合单细胞RNA-Seq数据,鉴定那些重叠的肾源性调控区,
发现它们与生物过程和临床表型的关联。我们将对顶级候选人进行功能测试
果蝇和肾类器官系统中的eQTL。在目标3中,我们将使用WGS数据来发现
由于已知的孟德尔原因导致的NS。我们将在美国患者中研究孟德尔NS的临床相关性,
确定与孟德尔疾病完全缓解相关的因素。最后,我们将使用
果蝇和类器官模型来功能性地筛选我们发现的假定致病变体。总的来说,
我们希望这些发现能扩大我们对NS相关遗传变异谱的了解,
这些窝藏他们的临床意义,其致病性的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW Gordon SAMPSON其他文献
MATTHEW Gordon SAMPSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW Gordon SAMPSON', 18)}}的其他基金
Whole Genome Sequencing for Nephrotic Syndrome Discovery
用于发现肾病综合征的全基因组测序
- 批准号:
10020397 - 财政年份:2019
- 资助金额:
$ 56.65万 - 项目类别:
Whole Genome Sequencing for Nephrotic Syndrome Discovery
用于发现肾病综合征的全基因组测序
- 批准号:
10477351 - 财政年份:2019
- 资助金额:
$ 56.65万 - 项目类别:
Whole Genome Sequencing for Nephrotic Syndrome Discovery
用于发现肾病综合征的全基因组测序
- 批准号:
10696083 - 财政年份:2019
- 资助金额:
$ 56.65万 - 项目类别:
Whole Genome Sequencing for Nephrotic Syndrome Discovery
用于发现肾病综合征的全基因组测序
- 批准号:
10250462 - 财政年份:2019
- 资助金额:
$ 56.65万 - 项目类别:
APOL1-associated nephropathy from a human-derived, intrarenal perspective
从人源肾内角度看 APOL1 相关肾病
- 批准号:
9080860 - 财政年份:2016
- 资助金额:
$ 56.65万 - 项目类别:
APOL1-associated nephropathy from a human-derived, intrarenal perspective
从人源肾内角度看 APOL1 相关肾病
- 批准号:
9896811 - 财政年份:2016
- 资助金额:
$ 56.65万 - 项目类别:
APOL1-associated nephropathy from a human-derived, intrarenal perspective
从人源肾内角度看 APOL1 相关肾病
- 批准号:
10078762 - 财政年份:2016
- 资助金额:
$ 56.65万 - 项目类别:
An Integrative Systems Genetics Approach to Nephrotic Syndrome
肾病综合征的综合系统遗传学方法
- 批准号:
8737893 - 财政年份:2013
- 资助金额:
$ 56.65万 - 项目类别:
An Integrative Systems Genetics Approach to Nephrotic Syndrome
肾病综合征的综合系统遗传学方法
- 批准号:
8616906 - 财政年份:2013
- 资助金额:
$ 56.65万 - 项目类别:
相似国自然基金
基于Pan-genome技术的沙门氏菌血清型特异性基因挖掘、功能分析及分子鉴定
- 批准号:31360388
- 批准年份:2013
- 资助金额:50.0 万元
- 项目类别:地区科学基金项目
基于Genome mining技术研究抑制表皮葡萄球菌生物膜形成的次级代谢产物
- 批准号:21242003
- 批准年份:2012
- 资助金额:10.0 万元
- 项目类别:专项基金项目
基于Pan-genome技术探究问号钩端螺旋体不同血清型致病性差异的遗传基础
- 批准号:81171587
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
相似海外基金
Using whole genome sequencing to identify non-coding elements associated with diabetes and related traits across ancestries
使用全基因组测序来识别与糖尿病相关的非编码元件和跨祖先的相关特征
- 批准号:
MR/Y003748/1 - 财政年份:2024
- 资助金额:
$ 56.65万 - 项目类别:
Research Grant
Evaluating scientific and ethical approaches to newborn screening with whole genome sequencing using large-scale population cohorts
使用大规模人群队列评估通过全基因组测序进行新生儿筛查的科学和伦理方法
- 批准号:
MR/X021351/1 - 财政年份:2024
- 资助金额:
$ 56.65万 - 项目类别:
Research Grant
Genetic basis of anticipation in multiplex autism families: a whole-genome sequencing study
多重自闭症家庭预期的遗传基础:全基因组测序研究
- 批准号:
23K14807 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Comprehensive Harmonization and Analysis of Case/Control Whole Genome Sequencing Data from the ALS/FTD Compute Project
来自 ALS/FTD 计算项目的病例/对照全基因组测序数据的全面协调和分析
- 批准号:
10592917 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
CIDR - UPGRADE WHOLE GENOME SEQUENCING ON 2,294 EXPERIMENTAL DNA SAMPLES FOR NCI, BEEBE-DIMMER
CIDR - 升级 NCI、BEEBE-DIMMER 2,294 个实验 DNA 样本的全基因组测序
- 批准号:
10949121 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
Identifying Cancer Tissue of Origin using Plasma Whole Genome Sequencing
使用血浆全基因组测序识别癌症组织起源
- 批准号:
488922 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
Operating Grants
TO PROVIDE SEQUENCING SERVICES USING WHOLE GENOME SEQUENCING (GERMLINE FFPE) FOR NCI (KLEIN)
为 NCI (KLEIN) 提供使用全基因组测序(种系 FFPE)的测序服务
- 批准号:
10949135 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
CIDR: SEQUENCING SERVICES USING WHOLE GENOME SEQUENCING FOR NCI (AMOS),
CIDR:使用 NCI 全基因组测序的测序服务 (AMOS),
- 批准号:
10949101 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
Quantifying replication dynamics to predict clonal evolution and drug sensitivity in cancer cells using single-cell whole genome sequencing
使用单细胞全基因组测序量化复制动态以预测癌细胞的克隆进化和药物敏感性
- 批准号:
10603140 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别:
Analysis of Somatic Mutations in Longitudinal Whole-genome Sequencing Data
纵向全基因组测序数据中的体细胞突变分析
- 批准号:
10836613 - 财政年份:2023
- 资助金额:
$ 56.65万 - 项目类别: